Related Experiment Video

Updated: Jan 4, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.9K

MCL1 as a Therapeutic Target in Parkinson's Disease?

Edward J Robinson1, Sebastian Aguiar2, Marten P Smidt1

  • 1Swammerdam Institute for Life Sciences, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, the Netherlands.

Trends in Molecular Medicine
|November 11, 2019
PubMed

Insights

Parkinson's disease selectively damages dopamine neurons. Targeting the Mcl1 protein, a survival factor, may offer a new therapeutic strategy to prevent neuron loss in Parkinson's disease.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Genetics

Background:

  • Dopamine neurons in the substantia nigra (SN) pars compacta are selectively vulnerable in Parkinson's disease (PD).
  • The Bcl2 family of proteins regulates neuronal survival and death.
  • Mcl1 has been identified as a critical survival factor for midbrain dopamine neurons.

Purpose of the Study:

  • To investigate the role of Mcl1 in the selective vulnerability of dopamine neurons in PD.
  • To explore the potential of targeting Mcl1 as a therapeutic strategy for Parkinson's disease.

Main Methods:

  • Analysis of Bcl2 family protein regulation in midbrain dopamine neurons.
  • Investigating the function of Mcl1 in neuronal survival pathways.

Main Results:

  • Mcl1 was identified as a key survival factor for dopamine neurons.
  • Dysregulation of Mcl1 may contribute to the selective loss of these neurons in PD.

Conclusions:

  • Targeting Mcl1 represents a potential therapeutic avenue to protect dopamine neurons.
  • Strengthening Mcl1 function could delay or prevent cell death in Parkinson's disease.
Keywords:
Bcl2apoptosiscell deathdopaminemitochondrianeurodegeneration

More Related Videos

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.8K
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

17.3K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
909
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K